Immunokinetic signatures of Helicobacter pylori infection: mechanistic insights for host immunity

Helicobacter pylori is a highly adaptable bacterial pathogen that affects nearly half of the global population and plays a significant role in chronic gastritis, peptic ulcer disease, and gastric carcinoma. The immunokinetic profile of H. pylori infection is characterized by a paradox of cellular response that does not eliminate the bacterium, alongside inconsistent mucosal antibody protection. Reported studies generally demonstrate an early increase in mucosal interleukin-8 (IL-8), followed by increased T helper 1 cells (Th1)- and T helper 17 cells (Th17)-associated cytokine responses, including interferon-γ (IFN-γ), interleukin-17 (IL-17), and tumor necrosis factor-α (TNF-α) Despite these strong proinflammatory responses, the bacterium continues to survive supported by regulatory T cells (Tregs), anti-inflammatory cytokines interleukin-10, transforming growth factor-β1 (IL-10, TGF-β1), and immune-evasion virulence proteins such as VacA (vacuolating cytotoxin A) and CagA (Cytotoxin-associated gene A). Serologically, anti- H. pylori IgG is prevalent and long-lived, whereas mucosal IgA responses are variable and generally insufficient for eradication, although they may contribute to partial control of bacterial load. Although these directional trends recur across studies, where cytokine concentrations fluctuate based on sampling methods and patient demographics, clear immunological patterns remain consistent across studies. Active infection is characterized by a generally associated with increased of gastric mucosal IL-8, whereas chronic carriage features a distinct imbalance marked by relatively elevated proinflammatory IFN-γ alongside comparatively modest levels of regulatory IL-10. The imbalance in immunokinetic responses between proinflammatory and anti-inflammatory networks, combined with the genetic diversity of both the host and the pathogen, plays a crucial role in determining clinical outcomes that range from asymptomatic colonization to the development of gastric malignancy. This conceptual synthesis may help identify research priorities and candidate immune patterns for future evaluation, although prospective validation is required before diagnostic, prognostic, or vaccine-related applications can be considered. This review integrates current evidence into an evidence-informed conceptual immunokinetic framework intended to generate testable hypotheses rather than define a universally fixed or clinically validated sequence of immune events.